Claims databases consisting of routinely collected longitudinal records of medical expenditures are increasingly utilized for estimating expected medical costs of patients with a specific condition. Survival data of the patients of interest are usually highly censored, and observed expenditures are incomplete. In this study, we propose a survival-adjusted estimator for estimating mean lifetime costs, which integrates the product of the survival function and the mean cost function over the lifetime horizon. The survival function is estimated by a new algorithm of rolling extrapolation, aided by external information of age- and sex-matched referents simulated from national vital statistics. The mean cost function is estimated by a weighted average of mean expenditures of patients in a number of months prior to their death, of which the number could be determined by observed costs in their final months, and the weights depend on extrapolated hazards. We evaluate the performance of the proposed approach in comparison with that of a popular method using simulated data under various scenarios and 2 cohorts of intracerebral hemorrhage and ischemic stroke patients with a maximum follow-up of 13 years and conclude that our new method estimates the mean lifetime costs more accurately.
The expected quality-adjusted survival (QAS) for an index population with a speci"c disease can be estimated by summing the product of the survival function and the mean quality of life function of the population. In many follow-up studies with heavy censoring, the expected QAS may not be well estimated due to the lack of data beyond the close of follow-up. In this paper, we "rst created a reference population from the life tables of the general population according to the Monte Carlo method. Secondly, we "tted a simple linear regression line to the logit of the ratio of quality-adjusted survival functions for the index and reference populations up to the end of follow-up. Finally, combining information on the reference population with the "tted line, we predicted the expected quality-adjusted survival curve beyond the follow-up period for the index population. Simulation studies have shown that the simple Monte Carlo estimation procedure is a potential approach for estimating expected QAS and the survival function beyond the follow-up with a certain degree of accuracy.
This study demonstrates the effectiveness using active safety surveillance to document safety of TCMs. This surveillance system could probably be useful to document the safety of other alternative or complementary medicines.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.